Abeona Therapeutics Announces Upcoming Financial Results
CLEVELAND, Abeona Therapeutics Inc. (NASDAQ: ABEO) is gearing up to host an important conference call to discuss its financial performance for the third quarter. This call is set for Wednesday at 8:30 a.m. ET, and it promises to offer insights into the company's progress and corporate developments.
Accessing the Conference Call
To join the call, interested participants can dial 877-545-0523 for U.S. attendees or 973-528-0016 for those calling internationally. It is advisable to call at least five minutes before the start time. For those who prefer listening online, a live webcast will be made available, and the replay will remain accessible for 30 days.
Participation in Major Healthcare Conference
Abeona is also set to engage in a fireside chat at a significant healthcare conference. This event will take place soon after the financial call, on Thursday at 1:20 p.m. Eastern Time. Investors can look forward to a comprehensive discussion regarding the company’s strategies and future directions.
How to Tune Into the Fireside Chat
For those interested in this event, the live webcast of the fireside chat can be found under the 'Events' section on Abeona's website. Like the financial call, this session will also have an archived replay available for a month post-event, ensuring that investors won't miss any critical information.
About Abeona Therapeutics
Abeona Therapeutics is a pioneering biopharmaceutical firm concentrating on developing innovative cell and gene therapies aimed at treating severe diseases. One of their flagship products, ZEVASKYN, is the first-ever autologous cell-based gene therapy specifically designed for treating wounds in both adults and children suffering from recessive dystrophic epidermolysis bullosa (RDEB). This leading-edge therapy is produced at Abeona's state-of-the-art manufacturing facility located in Cleveland, ensuring high-quality and effective treatments.
Focus on Advanced Gene Therapies
The company is also exploring state-of-the-art gene therapies utilizing adeno-associated viruses (AAV) for ophthalmic diseases that have significant unmet medical needs. Their advanced AAV capsids are currently under evaluation for a variety of serious conditions, emphasizing Abeona's commitment to innovation in addressing critical healthcare challenges.
For further information about Abeona Therapeutics, prospective investors can visit their official website for the latest updates and detailed insights into their therapeutic offerings.
Frequently Asked Questions
What is the purpose of Abeona's upcoming conference call?
The call will discuss the company’s third quarter financial results along with updates on corporate developments.
How can I participate in the conference call?
You can dial the respective phone numbers to join or access the live webcast on Abeona's website.
What is ZEVASKYN?
ZEVASKYN is an autologous cell-based gene therapy designed for treating wounds associated with recessive dystrophic epidermolysis bullosa.
Where is Abeona Therapeutics located?
The company is headquartered in Cleveland, Ohio, where they also operate their manufacturing facility.
What type of therapies is Abeona developing?
Abeona focuses on cell and gene therapies, particularly for severe diseases, and is exploring innovative AAV-based gene therapies for ophthalmic conditions.
